Physician profile
Bassel Artin
NPI 1124291273
$2,003.10
in general payments reported to CMS, 2019-2025
20 companies · $90.14 in 2025
The $90.14 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $123 · 2021: $190 · 2022: $85.79 · 2023: $737 · 2024: $68.49 · 2025: $90.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $418.58 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.86 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.97 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $147.10 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $145.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $142.59 | 2019-2023 | |
| Pfizer INC. | $118.04 | 2019-2025 | |
| Ge Healthcare | $102.52 | 2023 | |
| Boston Scientific Corporation | $101.95 | 2019-2022 | |
| Abiomed | $92.44 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $72.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $64.76 | 2019-2024 | Brilinta |
| Merck Sharp & Dohme LLC | $56.22 | 2022-2023 | Verquvo |
| Astellas Pharma US INC | $46.20 | 2019-2020 | |
| Amgen INC. | $44.65 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.81 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.93 | 2024 | Arcalyst |
| Medtronic, INC. | $16.11 | 2023 | Linq II |
| Novo Nordisk INC | $15.05 | 2019 | |
| Scpharmaceuticals INC. | $13.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Artin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.